|
|
 |
|
Viewing report
|
|
|
|
Merck & Co., Inc.: PharmaVitae Profile
Datamonitor, Nov 2010, Pages: 117
Introduction
This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Merck & Co.'s strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Merck & Co. over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Merck & Co.'s performance against key rivals in the prescription pharmaceutical sector.
- Assess the continued commercial and strategic impact of Merck & Co.'s 2009 acquisition of Schering-Plough.
- Key drivers from Merck’s newly expanded marketed and launch portfolios including Januvia, Isentress, Saphris and Simponi.
|
|
|
|
